DEVELOPMENT OF CLINICAL IMAGING DRUG ENHANCERS (DCIDE) Release Date: June 22, 2000 NOTICE: CA-00-018 National Cancer Institute The National Cancer Institute (NCI) announces a new program called Development of Clinical Imaging Drug Enhancers (DCIDE). DCIDE will make available to investigators, on a competitive basis, the preclinical development contract resources of NCI. The goal of DCIDE is the development of promising imaging molecular probes or enhancers (contrast agents) that are otherwise unlikely to undergo further development leading to Investigational New Drug (IND) application. DCIDE will assist the selected investigators by providing or facilitating any (or all) of the preclinical development requirements, including, for example, pharmacokinetics, dosimetry, and IND- directed toxicology. Assistance may also take the form of direction regarding regulatory affairs and access to probes for approved preclinical protocols. For more detailed information, visit the website, http://www.nci.nih.gov/bip/dcide.htm INQUIRIES Inquiries are encouraged, and the opportunity to clarify issues or answer questions is welcome. Inquiries may be directed to: DCIDE Biomedical Imaging Program National Cancer Institute 6130 Executive Blvd, EPN 800 Rockville, MD 20892 Phone: 301-496-9531 Fax: 301-480-5785 Email: tatumj@mail.nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||